Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Covington
Cantor Fitzgerald
US Army
Deloitte
AstraZeneca
Express Scripts
QuintilesIMS

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COTELLIC

« Back to Dashboard

Clinical Trials for Cotellic

Trial ID Title Status Sponsor Phase Summary
NCT01928394 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Recruiting Bristol-Myers Squibb Phase 1/Phase 2 To investigate the safety and efficacy of Nivolumab as a single agent or in combination with Ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of Nivolumab with Ipilimumab and Cobimetinib is also investigated in PC.
NCT02060188 A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) Recruiting Bristol-Myers Squibb Phase 1/Phase 2 The purpose of this study is to examine if Nivolumab alone, Nivolumab in combination with Ipilimumab, or Nivolumab in combination with Ipilimumab and Cobimetinib will demonstrate a meaningful objective response rate in patients with recurrent and metastatic colon cancer who also have a specific biomarker in their tumors.
NCT02091141 A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients Recruiting Genentech, Inc. Phase 2 This is a multicenter, non-randomized, open-label study designed to evaluate four treatment regimens in patients with advanced cancer for whom there is no available, beneficial treatment. Patients with HER2 overexpression, amplification, or -activating mutation will be treated with Herceptin/Perjeta; those with epidermal growth factor receptor (EGFR), with Tarceva; those with BRAF-activating mutation, with Zelboraf/Cotellic; and those with Hedehog pathway potentially clinically relevant mutation, with Erivedge. Treatment will continue until disease progression or unacceptable toxicity occurs. Study is expected to last up to 5 years.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cotellic

Condition Name

Condition Name for Cotellic
Intervention Trials
MSI Positive Colorectal Cancer 1
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 1
Clinical Stage III Cutaneous Melanoma AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cotellic
Intervention Trials
Melanoma 4
Carcinoma, Non-Small-Cell Lung 2
Neoplasm Metastasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cotellic

Trials by Country

Trials by Country for Cotellic
Location Trials
United States 70
United Kingdom 4
Spain 4
Italy 3
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cotellic
Location Trials
Tennessee 5
Massachusetts 5
California 4
Texas 4
Oregon 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cotellic

Clinical Trial Phase

Clinical Trial Phase for Cotellic
Clinical Trial Phase Trials
Phase 2 6
Phase 1/Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cotellic
Clinical Trial Phase Trials
Recruiting 7
Not yet recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cotellic

Sponsor Name

Sponsor Name for Cotellic
Sponsor Trials
Hoffmann-La Roche 3
National Cancer Institute (NCI) 3
Genentech, Inc. 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cotellic
Sponsor Trials
Industry 9
Other 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Baxter
Mallinckrodt
Fish and Richardson
Moodys
AstraZeneca
Deloitte
McKesson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.